Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

Not Recruiting

Trial ID: NCT01460160


The purpose of this study is to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia

Official Title

A Phase 2 Multi-Center, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Stanford Investigator(s)


For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

   - Newly diagnosed Philadelphia chromosome positive Acute Lymphoblastic Leukemia (ALL)

   - Age >1 year and < less than 18 years old

   - Induction chemotherapy ≤ 14 days according to institutional standard of care

   - Adequate liver, renal and cardiac function

Exclusion Criteria:

   - Prior treatment with a Oncogene fusion protein (BCR-ABL) inhibitor

   - Extramedullary involvement of the testicles

   - Active systemic bacterial, fungal or viral infection

   - Down syndrome


drug: Dasatinib

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Pediatric Hematology/Oncology

New Trial Alerts

Receive email alerts when trials open to patients.